Overall we demonstrated that TINC was able to flag normal samples with recurrent CHIP mutations, and to trigger a hybrid pipeline that includes tumour-only analysis in order to report the true extent of tumour mutations (including CHIP). This evidence concerns the gene STUB1 and neoplasm.